Heart Beat: January 2013

The U.S. Food and Drug Administration has approved the HeartWare Ventricular Assist System, as bridge therapy for heart failure patients awaiting heart transplantation. The left ventricular assist device (LVAD) fulfills the pumping duties of the left ventricle, which is responsible for pumping blood through the aorta to most of the body. LVADs, such as the HeartWare VAS, are meant to provide temporary assistance while a patient awaits the availability of a new heart.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access